Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 2/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28367574 | 0.88 | PSMB8 (0.39) | — | |
| SCHEMBL21904530 | 0.82 | CPT1A (0.36) | CPT1ACPT1BCPT2OPRL1 | |
| SCHEMBL21904525 | 0.75 | CPT1A (0.40) | CPT1ACPT1BCPT2CALCRLKMT2A | |
| SCHEMBL3578564 | 0.73 | CALCRL (0.46) | CALCRL | |
| SCHEMBL1274868 | 0.73 | CALCRL (0.46) | CALCRL | |
| SCHEMBL30804497 | 0.71 | OPRL1 (0.42) | OPRL1ALDH1A1 | |
| SCHEMBL21904215 | 0.71 | CALCRL (0.34) | CALCRLOPRL1 | |
| SCHEMBL25316481 | 0.69 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL31730579 | 0.69 | AAK1 (0.31) | — | |
| SCHEMBL31730509 | 0.69 | AAK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | CPT1A 1088/4885CPT1B 3319/4885CPT2 1856/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | CPT1A 1088/4885CPT1B 3319/4885CPT2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.